Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women
Cranston, Ross D.
Engstrom, Jarret C.
Brand, Rhonda M.
Schwartz, Jill L.
Carballo-Diéguez, AlexNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationMcGowan, I., R. D. Cranston, K. H. Mayer, I. Febo, K. Duffill, A. Siegel, J. C. Engstrom, et al. 2016. “Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.” PLoS ONE 11 (6): e0158310. doi:10.1371/journal.pone.0158310. http://dx.doi.org/10.1371/journal.pone.0158310.
AbstractObjectives: The purpose of Project Gel was to determine the safety and acceptability of rectal microbicides in young men who have sex with men (MSM) and transgender women (TGW) at risk of HIV infection. Methods: MSM and TGW aged 18–30 years were enrolled at three sites; Pittsburgh, PA; Boston, MA; and San Juan, PR. Stage 1A was a cross-sectional assessment of sexual health and behavior in MSM and TGW. A subset of participants from Stage 1A were then enrolled in Stage 1B, a 12-week evaluation of the safety and acceptability of a placebo rectal gel. This was followed by the final phase of the study (Stage 2) in which a subset of participants from Stage 1B were enrolled into a Phase 1 rectal safety and acceptability evaluation of tenofovir (TFV) 1% gel. Results: 248 participants were enrolled into Stage 1A. Participants’ average age was 23.3 years. The most common sexually transmitted infection (STIs) at baseline were Herpes simplex (HSV)-2 (16.1% by serology) and rectal Chlamydia trachomatis (CT) (10.1% by NAAT). 134 participants were enrolled into Stage 1B. During the 12 week period of follow-up 2 HIV, 5 rectal CT, and 5 rectal Neisseria gonorrhea infections were detected. The majority of adverse events (AEs) were infections (N = 56) or gastrointestinal (N = 46) and were mild (69.6%) or moderate (28.0%). Of the participants who completed Stage 1B, 24 were enrolled into Stage 2 and randomized (1:1) to receive TFV or placebo gel. All participants completed Stage 2. The majority of AEs were gastrointestinal (N = 10) and of mild (87.2%) or moderate (10.3%) severity. Conclusions: In this study we were able to enroll a sexually active population of young MSM and TGW who were willing to use rectal microbicides. TFV gel was safe and acceptable and should be further developed as an alternative HIV prevention intervention for this population. Trial Registration ClinicalTrials.gov NCT01283360
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27822381